Last reviewed · How we verify
Madopar
Madopar is a Small molecule drug developed by Max Planck Institute for Human Cognitive and Brain Sciences. It is currently in Phase 1 development. Also known as: Levodopa.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Madopar |
|---|---|
| Also known as | Levodopa |
| Sponsor | Max Planck Institute for Human Cognitive and Brain Sciences |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Effects of Levodopa-Benserazide Drug Combination on Periodontal Status in Patients With Parkinson's Disease
- Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study
- Dopamine and Brain Computer Interface (EARLY_PHASE1)
- Relative Bioavailability Study of HRG2010 in Healthy Subjects (PHASE1)
- Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease (PHASE2)
- Dopamine, Reward Learning and Sex Hormones (NA)
- Levodopa Benserazide Generic Formulation Versus the Originator (PHASE4)
- Behavioural Profiling of Disease-related Cognitive and Motor Impairment in PD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Madopar CI brief — competitive landscape report
- Madopar updates RSS · CI watch RSS
- Max Planck Institute for Human Cognitive and Brain Sciences portfolio CI
Frequently asked questions about Madopar
What is Madopar?
Who makes Madopar?
Is Madopar also known as anything else?
What development phase is Madopar in?
Related
- Manufacturer: Max Planck Institute for Human Cognitive and Brain Sciences — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Levodopa
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing